87results about How to "Small fluctuations in blood concentration" patented technology

The invention discloses high-glycosylation human growth hormone fusion protein. The human growth hormone fusion protein provided by the invention is characterized in that human growth hormone (hGH), flexible peptide joint (L), at least one human chorionic gonadotropin beta-subunit carboxyl terminated rigid peptide (CTP) and human immunoglobulin Fc fragments are sequentially contained from the end N to the end C. The invention also discloses a method for effectively preparing the fusion protein. The built fusion protein has more excellent in vivo medicine effect than recombination hGH; the in vivo circulation half-life period is prolonged; the medication administration frequency is greatly reduced; in addition, the bioavailability is improved; meanwhile, the production process is more simple and efficient.

The present invention relates to an olaparib oral controlled-release and sustained-release pharmaceutical composition, which contains dissolution form improved olaparib and a matrix polymer for release rate adjustment. According to the present invention, the in vivo absorption behavior, the blood drug level and the PARP enzyme inhibition level of the pharmaceutical composition can be controlled, the pharmaceutical composition has the improved olaparib loading and / or oral absorption and / or bioavailability and / or blood drug concentration control and / or enzyme inhibition level control, and can beused as the sole preparation or can be combined with other treatment methods in the treatment of cancer.

The invention relates to a solid self-emulsifying oral administration system of a fat-soluble dihydropyridine calcium ion antagonist and a preparation method thereof. The solid self-emulsifying oral administration system comprises a fat-soluble dihydropyridine calcium ion antagonist and a solid medicine transmission system. The preparation method comprises the following steps: taking an oil phase, a surfactant and a cosurfactant according to the quantity of a recipe, evenly mixing, adding a medicine according to the quantity of the recipe, stirring by magnetic force at 50 DEG C, completely dissolving and evenly mixing the medicine, and forming a uniform medicine-containing self-emulsifying system. If the system is in a solid state at room temperature, the system can be prepared into a self-emulsifying semisolid skeleton capsule after being heated and melted; the system also can be prepared into various oral solid preparation forms after the medicine-containing self-emulsifying system is solidified by adopting an adsorbent; and the system also can be prepared into corresponding slow-release and controlled-release solid preparations by selecting an appropriate skeleton material and a coating technique. The preparation method is simple and convenient, has low cost and is convenient for industrialized production, and the obtained solid preparation has diversified preparation forms, convenient taking, high bioavailability, stable blood concentration, good stability and convenient storage and transportation.

The invention provides a zinc gluconate pellet preparation, which is prepared from zinc gluconate and pharmaceutic adjuvant, and is characterized in that: the pharmaceutic adjuvant is an excipient and an adhesive, wherein in the pellet preparation, the weight percent of the zinc gluconate is 10 to 80 percent, the weight percent of the excipient is 12 to 89 percent and the weight percent of the adhesive is 1 to 8 percent. The pellet preparation can be prepared into a slow release preparation or an enteric-coated preparation. The zinc gluconate pellet preparation has high dissolution rate, and high bioavailability; and the method is simple, convenient, and easy to operate.

The invention provides a chondroitin sulfate pellet preparation, which is prepared from chondroitin sulfate and pharmaceutic adjuvant. The pellet preparation is characterized in that the pharmaceutic adjuvant is excipient and bonding agent, wherein the pellet preparation comprises the following components in percentage by weight: 10 to 90 percent of the chondroitin sulfate, 3 to 89 percent of the excipient, and 1 to 7 percent of the bonding agent. The pellet preparation can be prepared into a slow-release preparation or an enteric-coated preparation as requested. The chondroitin sulfate pellet preparation has high dissolution rate and high bioavailability, and the method is simple and convenient and is easy to operate.

The invention relates to a daphnetin slow-release composition and a preparation method thereof. The slow-release composition is a matrix tablet. The matrix tablet comprises daphnetin, filler, a matrix material, a bonding agent and a lubricating agent. The matrix material is a high-viscosity hydrophilic matrix material or a soluble matrix material. The daphnetin slow-release tablet prepared with the method has a good slow-release effect and is long in action time, low in dosage, low in frequency of taking and high in bioavailability in comparison with a capsule on the market. The process is simple in operation, low in cost and easy to control, and is suitable for industrial mass production.

The invention relates to a trimetazidine or salt sustained release capsule and a preparation method thereof. The trimetazidine sustained release capsule comprises the following components in percentage by weight: 5-50 percent of trimetazidine, 5-30 percent of auxiliary materials playing a role in sustained release and 45-85 percent if other auxiliary materials. The trimetazidine sustained release capsule and the preparation method thereof are characterized in that (1), a capsule content is a pellet; (2), the medicated pellet is firstly prepared, and a sustained release preparation is then prepared; and (3), the release of a drug is controlled through a controlled release membrane enwrapped by the pellet.

The invention discloses a niraparib oral controlled-release and sustained-release pharmaceutical composition and uses thereof. According to the presebt invention, by regulating the niraparib release behavior, the in vivo absorption rate and the absorption time of niraparib can be controlled, and the blood concentration and the blood concentration fluctuation range of niraparib in vivo can be regulated, such that the in vivo PARP enzyme inhibition activity of niraparib can be efficiently and permanently provided so as to provide the antitumor treatment effect in the high-efficiency and low-toxicity manner; a purpose of the present invention is to control the in vivo blood concentration and the efficacy providing of niraparib through the controlled-release and sustained-release preparation so as to improve the treatment effect of the drug and reduce the toxic-side effect of the drug; and the efficient and long-acting PARP enzyme activity inhibition pharmaceutical composition is providedfor patients, wherein the antitumor effect is improved, the acting time is long, the compliance is good, and the toxic-side effect is low.

The invention relates to a preparation method of a pharmaceutical composition for treating type II diabetes, belonging to the medical preparations containing organic ingredients, particularly relating to a preparation method of a pharmaceutical composition of metformin hydrochloride and glimepiride. In the preparation method, the metformin hydrochloride and the glimepiride are taken as active ingredients of the pharmaceutical composition, the metformin hydrochloride is firstly prepared into pill cores by adopting an osmotic pump technology and then the metformin hydrochloride pill cores are coated with the glimepiride by using a coating technology. The preparation method comprises the following steps: 1), preparing the metformin hydrochloride and pharmaceutically acceptable auxiliary materials into pills which are coated with semipermeable membrane layers, punching by laser and producing the pill cores; and 2), preparing the glimepiride and the pharmaceutically acceptable auxiliary materials into a coating liquid dissolved in stomach and carrying out coating on the pill cores in step 1. The invention provides the preparation method of the pharmaceutical composition for treating the type II diabetes, wherein the pharmaceutical composition steady and slowly releases drugs, has reduced administration times, good patients compliance, small side effect and small tablet volume, is less influenced by pH values of different segments of a gastrointestinal tract, and is convenient for administration for the patients.